Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions

SIMPLE SUMMARY: Upper tract urothelial carcinoma (UTUC) represents 5 to 10% of urothelial carcinoma. Their mutational profile is different as compared to bladder urothelial carcinoma (UC). While immune checkpoint inhibitors are now part of the therapeutic landscape of urothelial carcinoma, data conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Thouvenin, Jonathan, Martínez Chanzá, Nieves, Alhalabi, Omar, Lang, Hervé, Tannir, Nizar M., Barthélémy, Philippe, Malouf, Gabriel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431384/
https://www.ncbi.nlm.nih.gov/pubmed/34503152
http://dx.doi.org/10.3390/cancers13174341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431384/
https://www.ncbi.nlm.nih.gov/pubmed/34503152
http://dx.doi.org/10.3390/cancers13174341

Ejemplares similares